文献园地
更多
TheranosticsDevelopment of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment
International ImmunopharmacologySiglec-E deletion alters AT macrophages phenotypes, induces an inflammatory response, and adipogenesis during diet-induced obesity
Journal of Orthopaedic ResearchDepth-Wise Changes in Tibial and Femoral Human Knee Joint Cartilage at Different Severities of Osteoarthritis
品牌库
更多tranScrip Ltd
Established in October 2008, TranScrip Partners was specifically created to meet the needs of pharmaceutical companies forced to reduce head counts and consequent access to in-house drug development expertise. TranScrip is structured to fill this gap in the market and can provide pharmaceutical and life science companies with the expertise they require in a wide range of sub-disciplines and therapeutic areas, on both a short and long term basis, drawn from its extensive pool of Senior Partners and Partners.
Abbott B.V.
We are a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. Our products span the continuum of care, from nutritional products and laboratory diagnostics through medical devices and pharmaceutical therapies. Our comprehensive line of products encircles life itself - addressing important health needs from infancy to the golden years.
Formatech, Inc. Company dissolved
At Formatech, we help make new drugs happen… at the speed of science! Formatech, founded in 1993, provides contract services that deliver unique solutions to our clients' product development and manufacturing challenges. Our service offerings include: preformulation and formulation development of all common dosage forms, lyophilization development, cell culture/fermentation process development, purification/downstream process development and aseptic fill and finish of liquid and lyophilized dosage units. We have had excellent results developing biotherapeutic products. Our accomplishments include developing many Ab formulations at concentrations in excess of 200 mg/mL and an orally bioavailable peptide formulation. Our aseptic manufacturing facility produces liquid and lyophilized dosage units for clinical supplies or small-scale commercial products. Manufacturing support services include compounding/formulation, diafiltration/concentration (UF/DF), release testing, and ICH conforming stability programs. Our team is accomplished at completing new projects successfully even when confronted with very aggressive timelines. Our regulatory history includes FDA inspections and three inspections by the MHRA (letters and certificate of GMP compliance received).
GUS Schweiz AG
We optimize your business processes GUS ERP GmbH, GUS Nordic ApS and GUS Schweiz AG provide GUS-OS Suite, a web-based ERP business solution that includes all industry functionalities and fulfills regulatory requirements. The companies are members of the GSG GENII Software Group (www.gsg-genii.com), which offers leading, industry-specific software solutions and services, explicitly for medium-sized companies and public administrations. With its industry knowledge and personal customer relationships, the group of companies is a trustworthy partner and expert advisor to its customers. It accompanies its customers through digitization and ensures that they are equipped for the future in a volatile environment. GENII, headquartered in Munich, Germany, has generated sales of approximately 340 million euros with around 2,400 employees. GENII is backed by Bregal Unternehmerkapital and Elvaston.
GUS ERP GmbH
As a long-standing partner of the process industry, the GUS Group combines business competence with industry expertise and offers with GUS-OS ERP one of the most comprehensive software offerings for companies in the pharmaceutical, biotechnology, cosmetics, food and beverage, chemical and logistics industries. The GUS Group provides comprehensive consulting services, carries out projects and sets up IT infrastructures. Our own development team ensures continuous software innovations and the alignment of the solution with the norms and standards in our target industries. Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here .
Dr. August Wolff GmbH & Co. KG
Dr. August Wolff GmbH & Co. KG Arzneimittel is a family owned research oriented company still located in Bielefeld, Germany. Dr. August Wolff GmbH & Co. KG is selling medicinal products, medical devices and cosmetic products like Linola and Vagisan in several European countries. Since its inception in 1905 Dr. August Wolff has maintained strong focus in collaborations with universities to foster research and development in their search for novel products.
生知快讯
最新资讯
更多
Open Access Journal of Clinical Trials：临床研究设计、真实世界临床试验、临床试验伦理规范投稿必备的影响因子、收录偏好与通关技巧
一、领域背景与期刊定位2024-2025年临床试验领域研究热点聚焦去中心化临床试验（DCT）方法优化、真实世界证据（RWE）支持新药注册、罕见病小样本临床试验设计、AI辅助受试者招募与数据质控等方向，领域投稿痛点突出：82%的临床类期刊拒稿源于研究设计不符合CONSORT规范、伦理材料缺失或未完成临床试验前置注册^中科院文献情
Reviews on Recent Clinical Trials：新药临床试验设计/真实世界临床研究/转化临床诊疗评估 投稿必备的影响因子、收录偏好与通关技巧
一、领域背景与期刊定位2024-2025年全球临床研究领域聚焦AI辅助临床试验入组优化、罕见病单臂试验审评标准落地、真实世界证据支持新药获批三大核心方向，相关综述类成果投稿量年涨幅达32%，但75%的拒稿源于内容时效性不足、未覆盖最新注册临床试验数据，与期刊定位不匹配^中科院文献情报中心 2025^。《Reviews on Recent Cl
Computer Methods and Programs in Biomedicine Update：生物医学计算与医学信息学技术 投稿必备的影响因子、收录偏好与通关技巧
---一、领域背景与期刊定位2024-2025年生物医学计算领域聚焦医疗大模型落地验证、多组学数据工具开发、可穿戴设备慢病预警算法、电子健康记录智能挖掘四大研究方向，领域投稿痛点突出：78%的拒稿源于研究仅包含纯计算机理论设计，未匹配生物医学/临床实际应用场景，与期刊定位偏差较大^中科院文献情报中心2025^。《Computer